| Catalog No. | HF977036 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG4-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | Transforming growth factor beta-1 proprotein, LAP, TGF-beta-1, TGFB1, TGFB, GARP, Leucine-rich repeat-containing protein 32, Glycoprotein A repetitions predominant, D11S833E, Garpin, Transforming growth factor beta activator LRRC32, LRRC32 |
|---|
| Concentration | 0.81mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P01137 & Q14392 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -753°C. |
|---|
| Alternate Names | Bispecific,ABBV-151,ARGX-115,MHG-8,MHGARP-8,PR-1762844CAS:2412004-88-5 |
|---|
| Background | Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
